Form 4: Arcutis Biotherapeutics Director Terrie Curran Reports Significant Equity Grants

Arcutis Biotherapeutics, Inc. Director Terrie Curran reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options with an exercise price of $13.5, granted for her service.

Summary

• Terrie Curran, a Director at Arcutis Biotherapeutics, Inc. (ARQT), reported the acquisition of 7,609 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 12, 2025.
• These RSUs were granted as compensation for her service as a non-employee director and have a grant price of $0.
• The RSUs are set to vest on the earlier of June 12, 2025 (the first anniversary of the grant date) or immediately before the next annual meeting of stockholders, contingent on her continued service.
• Upon vesting, the settlement of these RSUs has been deferred by Ms. Curran, as per the RSU Deferral Election Form adopted on December 16, 2024.
• Following this transaction, Ms. Curran beneficially owns 17,748 shares of Common Stock.
• Additionally, Ms. Curran acquired 20,568 stock options with an exercise price of $13.5 on June 12, 2025.
• These stock options will vest and become exercisable as to 100% on the earlier of June 12, 2025 (the first anniversary of the grant date) or immediately before the next annual meeting of stockholders, subject to her continued service.
• The stock options have an expiration date of June 12, 2035.
• Following this transaction, Ms. Curran beneficially owns 20,568 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person as they received significant equity compensation. For the company, it's a neutral event as it represents expected compensation, aligning director interests with shareholders, which is generally viewed favorably.

Positives

• The grant of Restricted Stock Units and stock options to Director Terrie Curran aligns her interests with those of the shareholders, incentivizing long-term performance.
• The RSU deferral mechanism allows the director flexibility in managing her equity compensation.

Future Outlook

The document details compensation grants and does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across publicly traded companies, particularly in the biotechnology sector, to align director incentives with company performance. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The grants represent a form of compensation that aligns the director's interests with shareholder value creation, though they also involve a minor dilutive effect from the issuance of new shares upon vesting/exercise.
• Employees: No direct impact mentioned for employees.
• Customers: No direct impact mentioned for customers.
• Suppliers: No direct impact mentioned for suppliers.
• Creditors: No direct impact mentioned for creditors.

Next Steps

• Vesting of the 7,609 Restricted Stock Units on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders.
• Vesting of the 20,568 stock options on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders.
• Potential exercise of stock options by Terrie Curran before their expiration on June 12, 2035.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership